{"id":"CHEMBL1010","canonicalSmiles":"CO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(C)=O)CS[C@H]12)c1csc(N)n1.[Na+]","inchiKey":"AZZMGZXNTDTSME-JUZDKLSSSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"CEFOTAXIME SODIUM","yearOfFirstApproval":1981,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1730","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cefcil","Cefotaxime","Cefotaxime sodium","Claforan","Pretor"],"synonyms":["Cefotaxime sodium","Cefotaxime sodium salt","HR 756","HR-756","NSC-756666","RU 24756","RU-24756","Sodium cefotaxime"],"crossReferences":{"DailyMed":["cefotaxime%20sodium"],"PubChem":["50106035","56422770","85149186","85273722"],"chEBI":["3498"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 1 investigational indication."}
{"id":"CHEMBL1057","canonicalSmiles":"O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21","inchiKey":"GNBHRKFJIUUOQI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1057","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144207049","144213816","26755297","29216383"],"drugbank":["DB00693"],"chEBI":["31624"]},"childChemblIds":["CHEMBL1200433"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1090479","canonicalSmiles":"CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1","inchiKey":"QTBWCSQGBMPECM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GSK-1070916","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GSK 1070916A","GSK1070916","Gsk-1070916","Gsk-1070916a"],"linkedTargets":{"rows":["ENSG00000178999","ENSG00000105146"],"count":2},"linkedDiseases":{"rows":["EFO_0000616"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1095292","canonicalSmiles":"CC[N+](C)(C)Cc1ccccc1Br.Cc1ccc(S(=O)(=O)[O-])cc1","inchiKey":"KVWNWTZZBKCOPM-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"BRETYLIUM TOSYLATE","yearOfFirstApproval":1986,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1199080","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Bretylium tosylate","Bretylol"],"synonyms":["ASL-603","Bretylium tosilate","Bretylium tosylate","NSC-62164"],"crossReferences":{"PubChem":["11111997","11111998","50104303","85231294","855621"],"chEBI":["3173"]},"linkedTargets":{"rows":["ENSG00000103546"],"count":1},"linkedDiseases":{"rows":["EFO_0004269","EFO_0004287","HP_0004308"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 3 approved indications."}
{"id":"CHEMBL1103","canonicalSmiles":"O=C1OCCN1/N=C/c1ccc([N+](=O)[O-])o1","inchiKey":"PLHJDBGFXBMTGZ-WEVVVXLNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FURAZOLIDONE","yearOfFirstApproval":1958,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Furall","Furoxone"],"synonyms":["Furazolidone","NSC-6469","Nifurazolidone"],"crossReferences":{"PubChem":["144205055","170464641","26749310","29215179"],"Wikipedia":["Furazolidone"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1958."}
{"id":"CHEMBL1133","canonicalSmiles":"CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1.Cl","inchiKey":"SWIJYDAEGSIQPZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXYBUTYNIN CHLORIDE","yearOfFirstApproval":1975,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1231","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ditropan","Ditropan xl","Gelnique","Oxybutynin chloride"],"synonyms":["5058","MJ 4309-1","MJ-4309-1","NSC-759108","Oxybutynin chloride","Oxybutynin hydrochloride","Pollakisu","Tropax"],"crossReferences":{"DailyMed":["oxybutynin%20chloride"],"PubChem":["144204058","50106787","50106788","56422498","855604"],"chEBI":["7857"]},"linkedTargets":{"rows":["ENSG00000133019","ENSG00000181072"],"count":2},"linkedDiseases":{"rows":["EFO_0006865","HP_0000020","EFO_1000781","EFO_0001663"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and is indicated for overactive bladder and has 2 investigational indications."}
{"id":"CHEMBL1169","canonicalSmiles":"Nc1ccc(C(=O)O)c(O)c1","inchiKey":"WUBBRNOQWQTFEX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMINOSALICYLIC ACID","yearOfFirstApproval":1950,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Granupas","Parasal","Paser","Rezipas"],"synonyms":["4-aminosalicylic acid","Aminosalicylate","Aminosalicylic Acid","Aminosalicylic acid","Aminosalicylic acid resin complex","Benzoic acid, 4-amino-2-hydroxy-","NSC-2083","P-aminosalicylic acid","Para-aminosalicylic acid","Pas","Paskalium","Teebacin"],"crossReferences":{"DailyMed":["aminosalicylic%20acid"],"PubChem":["29215427","56422457","855553"],"Wikipedia":["4-Aminosalicylic_acid"],"drugbank":["DB00233"],"chEBI":["27565"]},"childChemblIds":["CHEMBL2105983","CHEMBL2096646","CHEMBL1343453","CHEMBL1200584","CHEMBL1200966","CHEMBL1378207"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for tuberculosis and has 4 investigational indications."}
{"id":"CHEMBL1189025","canonicalSmiles":"C=C(Br)C(=O)Nc1cc(C(=O)Nc2cc(C(=O)Nc3cc(C(=O)Nc4cc(C(=O)NCCN=C(N)N)n(C)c4)n(C)c3)n(C)c2)n(C)c1","inchiKey":"RXOVOXFAAGIKDQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BROSTALLICIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Brostallicin"],"crossReferences":{"drugbank":["DB06598"]},"childChemblIds":["CHEMBL537929"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL1200951","canonicalSmiles":"CCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1","inchiKey":"LRWSFOSWNAQHHW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLUPHENAZINE ENANTHATE","yearOfFirstApproval":1967,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Moditen enant","Prolixin","Prolixin enanthate"],"synonyms":["Flufenan","Fluphenazine","Fluphenazine enantate","Fluphenazine enanthate","Fluphenazine maleate","Fluphenazini enantas","SQ 16,114","SQ 16144"],"crossReferences":{"chEBI":["5125"]},"linkedTargets":{"rows":["ENSG00000149295"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090","MONDO_0002050","HP_0000726","EFO_0000676","EFO_0005407","EFO_0005230","EFO_0005411"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for psychosis and has 5 investigational indications."}
{"id":"CHEMBL1201064","canonicalSmiles":"CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C","inchiKey":"YRFXGQHBPBMFHW-SBTZIJSASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLUOROMETHOLONE ACETATE","yearOfFirstApproval":1986,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Flarex"],"synonyms":["Fluorometholone 17-acetate","Fluorometholone acetate","NSC-47438","U-17,323","U-17323"],"crossReferences":{"DailyMed":["fluorometholone%20acetate"],"PubChem":["100431"],"chEBI":["78354"]},"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["EFO_0009552","EFO_0003894","EFO_0005752"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 3 approved indications."}
{"id":"CHEMBL1201167","canonicalSmiles":"COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12.O=P(O)(O)O","inchiKey":"XCPXNPBILMXKNX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CARVEDILOL PHOSPHATE","yearOfFirstApproval":2006,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL723","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Coreg cr"],"synonyms":["Carvedilol phosphate","Carvedilol phosphate hemihydrate","Carvedilol phosphate hydrate","SK&F-105517-D","SKF 105517D","SKF-105517D"],"crossReferences":{"DailyMed":["carvedilol%20phosphate"]},"linkedTargets":{"rows":["ENSG00000169252","ENSG00000171873","ENSG00000170214","ENSG00000120907","ENSG00000043591","ENSG00000188778"],"count":6},"linkedDiseases":{"rows":["MONDO_0007254","EFO_0000373","EFO_0000612","EFO_0000537"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for hypertension and myocardial infarction and has 1 investigational indication."}
{"id":"CHEMBL1201723","drugType":"Unknown","blackBoxWarning":false,"name":"SINECATECHINS","yearOfFirstApproval":2006,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Veregen"],"synonyms":["Camellia sinensis catechins","Camellia sinensis leaf catechins","Kunecatechins","Polyphenon e","Sinecatechins"],"crossReferences":{"DailyMed":["sinecatechins"],"DrugCentral":["4785"]},"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for viral disease and has 3 investigational indications."}
{"id":"CHEMBL1201724","drugType":"Unknown","blackBoxWarning":false,"name":"POVIDONE-IODINE","yearOfFirstApproval":1985,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Betadine","Betadine vc kit","Betasept","Codella","E-z prep","E-z prep 220","E-z scrub","E-z scrub 201","E-z scrub 241","Povidone iodine"],"synonyms":["NSC-26245","Povidone iodine","Povidone-iodine","Pvp-iodine"],"crossReferences":{"DailyMed":["povidone-iodine"],"DrugCentral":["4249"],"Wikipedia":["Povidone-iodine"]},"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 14 investigational indications."}
{"id":"CHEMBL1201863","canonicalSmiles":"Cc1c(OCC(F)(F)F)ccnc1C[S@@+]([O-])c1nc2ccccc2[nH]1","inchiKey":"MJIHNNLFOKEZEW-RUZDIDTESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEXLANSOPRAZOLE","yearOfFirstApproval":2009,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dexilant","Dexilant solutab","Kapidex"],"synonyms":["(r)-lansoprazole","Dexlansoprazole","Kapidex","Lansoprazole r-form","Lansoprazole, (r)-","NSC-758710","T-168390","TAK-390"],"crossReferences":{"DailyMed":["dexlansoprazole"],"Wikipedia":["Dexlansoprazole"],"drugbank":["DB05351"]},"linkedTargets":{"rows":["ENSG00000105675"],"count":1},"linkedDiseases":{"rows":["EFO_0003948","EFO_0009454","HP_0004398","EFO_0000280","EFO_0004607","EFO_1000961","HP_0100633","EFO_1001095"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 5 approved and 2 investigational indications."}
{"id":"CHEMBL1223852","canonicalSmiles":"CC1=C(C)C(=O)C(CC[C@](C)(O)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C1=O","inchiKey":"LTVDFSLWFKLJDQ-IEOSBIPESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"Alpha-Tocopherylquinone","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Alpha-Tocopherylquinone"],"crossReferences":{"drugbank":["DB14094"]},"childChemblIds":["CHEMBL4293169"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1231267","canonicalSmiles":"OCCCCCCCCCCCCBr","inchiKey":"ASIDMJNTHJYVQJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1231267","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144210020"],"drugbank":["DB02619"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1236315","canonicalSmiles":"O=C(O)[C@H](O)[C@@H](O)C(=O)O","inchiKey":"FEWJPZIEWOKRBE-JCYAYHJZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TARTRATE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["E 334","E-334","FEMA NO. 3044","INS NO.334","INS-334","L-tartaric acid","NSC-62778","Tartaric acid","Tartrate"],"crossReferences":{"PubChem":["144210475","57264380"],"drugbank":["DB09459"],"chEBI":["15671"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1236704","canonicalSmiles":"Nc1c[nH]c(=O)[nH]c1=O","inchiKey":"BISHACNKZIBDFM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"5-Aminouracil","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["5-Aminouracil"],"crossReferences":{"drugbank":["DB03792"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1241855","canonicalSmiles":"COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1","inchiKey":"OWBFCJROIKNMGD-BQYQJAHWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RIGOSERTIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ON 01910","Rigosertib"],"crossReferences":{"drugbank":["DB12146"]},"childChemblIds":["CHEMBL2013119"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications."}
{"id":"CHEMBL1256734","canonicalSmiles":"CC1(C)S[C@@H]2[C@H](NC(=O)C(c3ccccc3)S(=O)(=O)O)C(=O)N2[C@H]1C(=O)O","inchiKey":"JETQIUPBHQNHNZ-OAYJICASSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULBENICILLIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[".alpha.-sulfobenzylpenicillin","D-(-)-sulbenicillin","Sulbenicillin","Sulbenicillin sodium","Sulfobenzylpenicillin"],"crossReferences":{"chEBI":["9322"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1289494","canonicalSmiles":"COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC","inchiKey":"SPMVMDHWKHCIDT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TIVOZANIB","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Fotivda"],"synonyms":["ASP-4130","AV-951","KIL8951","KRN-951","Kil-8951","Krn-951","Tivozanib"],"crossReferences":{"PubChem":["124955473"],"Wikipedia":["Tivozanib"],"drugbank":["DB11800"]},"childChemblIds":["CHEMBL2105756","CHEMBL3426917","CHEMBL4784300"],"linkedTargets":{"rows":["ENSG00000128052","ENSG00000102755","ENSG00000037280","ENSG00000157404","ENSG00000113721"],"count":5},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0015686","EFO_0000681","MONDO_0008170","MONDO_0007254","EFO_1001968","EFO_0003060","EFO_0005221","MONDO_0008315","EFO_1001951","EFO_1001480","EFO_1000218","MONDO_0002158","EFO_0000182","EFO_0001421","EFO_0000519"],"count":16},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for neoplasm and renal cell carcinoma and has 13 investigational indications."}
{"id":"CHEMBL1331216","canonicalSmiles":"CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)[C@H](CO)c1ccccc1)C2","inchiKey":"RKUNBYITZUJHSG-FXUDXRNXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HYOSCYAMINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["(-)-atropine","(-)-hyoscyamine","(s)-(-)-hyoscyamine","Atropine, (s)-","Bellafoline","Cystospaz","Daturine","Duboisine","Hyoscyamine","Hyoscyaminum","L-hyoscyamine","NSC-757064"],"crossReferences":{"PubChem":["50085944"],"drugbank":["DB00424"],"chEBI":["17486"]},"childChemblIds":["CHEMBL1697729","CHEMBL2106364","CHEMBL3989570"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for gastrointestinal disease and urinary tract infection."}
{"id":"CHEMBL1384","canonicalSmiles":"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O","inchiKey":"SBUJHOSQTJFQJX-NOAMYHISSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"KANAMYCIN","yearOfFirstApproval":1973,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Kanamycin","Kanamycins"],"crossReferences":{"Wikipedia":["Kanamycin"],"drugbank":["DB01172"],"chEBI":["17630"]},"childChemblIds":["CHEMBL4751482","CHEMBL1446"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for bacterial disease and eye infection and has 4 investigational indications."}
{"id":"CHEMBL140000","canonicalSmiles":"CN(C)c1ccc(C(=O)NCCCCCCC(=O)NO)cc1","inchiKey":"MXWDSZWTBOCWBK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL140000","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["534548"],"drugbank":["DB02565"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1411","canonicalSmiles":"C[C@@H](O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O","inchiKey":"NSMXQKNUPPXBRG-SECBINFHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LISOFYLLINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Protec"],"synonyms":["CT 1501R","CT-1501R","Lisofylline","Lisofylline, (r)-"],"crossReferences":{"Wikipedia":["Lisofylline"],"drugbank":["DB12406"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1450","canonicalSmiles":"O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21","inchiKey":"KUCQYCKVKVOKAY-CTYIDZIISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ATOVAQUONE","yearOfFirstApproval":1992,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Atovaquone","Mepron","Wellvone"],"synonyms":["566C","566C80","Atovaquone","Mepron","NSC-759582"],"crossReferences":{"DailyMed":["atovaquone"],"PubChem":["144204265","170464681"],"Wikipedia":["Atovaquone"],"drugbank":["DB01117"],"chEBI":["575568"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for pneumocystosis and malaria and has 6 investigational indications."}
{"id":"CHEMBL1477","canonicalSmiles":"COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1","inchiKey":"SEERZIQQUAZTOL-ANMDKAQQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CERIVASTATIN","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"],"classes":["Musculoskeletal toxicity"," Nephrotoxicity"],"year":2001},"tradeNames":["Lipobay"],"synonyms":["Baycol","Cerivastatin","Lipobay"],"crossReferences":{"PubChem":["50111694"],"Wikipedia":["Cerivastatin"],"drugbank":["DB00439"],"chEBI":["3558"]},"childChemblIds":["CHEMBL1200563"],"linkedTargets":{"rows":["ENSG00000113161"],"count":1},"linkedDiseases":{"rows":["EFO_0000319"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997 and is indicated for cardiovascular disease. It was withdrawn in United States  in 2001 due to Musculoskeletal toxicity and  Nephrotoxicity."}
{"id":"CHEMBL1652611","canonicalSmiles":"CC[C@@H]1CCN[C@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)C1","inchiKey":"HBJOXQRURQPDEX-MHXMMLMNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PIRLIMYCIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Pirlimycin","Pirsue"],"crossReferences":{"Wikipedia":["Pirlimycin"],"drugbank":["DB11537"]},"childChemblIds":["CHEMBL3989899"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1688529","canonicalSmiles":"C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C","inchiKey":"RPJPZDVUUKWPGT-FOIHOXPVSA-N","drugType":"Protein","blackBoxWarning":false,"name":"NIM811","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NIM811","Nim-811","Nim811"],"crossReferences":{"Wikipedia":["NIM811"],"drugbank":["DB13068"]},"description":"Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1715","canonicalSmiles":"CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1.Cl","inchiKey":"GHUUBYQTCDQWRA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"PIOGLITAZONE HYDROCHLORIDE","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL595","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Actos","Diabiom","Glidipion","Glizofar","Pioglitazone hydrochloride"],"synonyms":["Actos","NSC-758876","Pioglitazone (as hydrochloride)","Pioglitazone hcl","Pioglitazone hydrochloride","Piomed","STR-001","U-72107A"],"crossReferences":{"DailyMed":["pioglitazone%20hydrochloride"],"PubChem":["144204993","144210901","170465116","26748968","49681546"]},"linkedTargets":{"rows":["ENSG00000132170"],"count":1},"linkedDiseases":{"rows":["EFO_0002618","HP_0002745","EFO_0003095","MONDO_0002009","EFO_0003884","EFO_0001421","MONDO_0004976","MONDO_0005148","EFO_0003060"],"count":9},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for liver disease and type 2 diabetes mellitus and has 7 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1727","canonicalSmiles":"CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1","inchiKey":"ZAIPMKNFIOOWCQ-UEKVPHQBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEPHALEXIN","yearOfFirstApproval":1971,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Keflet","Keflex"],"synonyms":["66873","Cefalexin","Cephalexin","Keflet","Keflex","Keftab"],"crossReferences":{"DailyMed":["cephalexin"],"PubChem":["144205293","170464982","26719711","29215501"],"Wikipedia":["Cefalexin"],"drugbank":["DB00567"],"chEBI":["3534"]},"childChemblIds":["CHEMBL1200366","CHEMBL1200544"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 6 approved and 11 investigational indications."}
{"id":"CHEMBL1731","canonicalSmiles":"CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(S(C)(=O)=O)C3=O)c3ccccc3)C(=O)N2[C@H]1C(=O)O","inchiKey":"YPBATNHYBCGSSN-VWPFQQQWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MEZLOCILLIN","yearOfFirstApproval":1981,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Baypen","Multocillin"],"synonyms":["BAY-F-1353","Mezlocillin"],"crossReferences":{"PubChem":["144206027"],"Wikipedia":["Mezlocillin"],"drugbank":["DB00948"],"chEBI":["6919"]},"childChemblIds":["CHEMBL1697708"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for bacterial disease and has 1 investigational indication."}
{"id":"CHEMBL1743021","drugType":"Antibody","blackBoxWarning":false,"name":"FORAVIRUMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CR-4098","CR4098","Foravirumab"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1743041","drugType":"Antibody","blackBoxWarning":false,"name":"MOGAMULIZUMAB","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Poteligeo"],"synonyms":["AMG-761","KM-8761","KM8761","KW-0761","Mogamulizumab","Mogamulizumab (genetical recombination)","Mogamulizumab-kpkc"],"crossReferences":{"DailyMed":["mogamulizumab-kpkc"],"DrugCentral":["5031"]},"linkedTargets":{"rows":["ENSG00000183813"],"count":1},"linkedDiseases":{"rows":["EFO_0000211","EFO_0000616","MONDO_0019471","MONDO_0044889","EFO_0002913","EFO_0000182","MONDO_0004979","EFO_1001051","EFO_0000313","EFO_0002426","EFO_1000785","EFO_0007527","EFO_0003060"],"count":13},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 8 investigational indications."}
{"id":"CHEMBL175083","canonicalSmiles":"Nc1nc(O)c(N)c(O)n1","inchiKey":"HWSJQFCTYLBBOF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL175083","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02037"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1774080","canonicalSmiles":"O=C1CCc2ccc(OCCCCN3CCN(c4cccc5ccccc45)CC3)nc2N1","inchiKey":"QGNOXTFZOLDODX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PF-00217830","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["J2.975.999E","PF-00217830","PF-217830","Pf-00217830"],"crossReferences":{"drugbank":["DB12998"]},"linkedTargets":{"rows":["ENSG00000149295"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL178","canonicalSmiles":"COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1","inchiKey":"STQGQHZAVUOBTE-VGBVRHCVSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"DAUNORUBICIN","yearOfFirstApproval":1979,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Daunoxome"],"synonyms":["Cerubidine","Daunomycin","Daunorubicin","Daunoxome","Epirubicin hydrochloride impurity, daunorubicin-","FI 6339","FI-6339","NSC-83142","RP 13057","RP-13057","Valrubicin impurity, daunorubicin"],"crossReferences":{"DailyMed":["daunorubicin","daunorubicin%20hydrochloride"],"PubChem":["11114094","144204447","170465048","29215022"],"Wikipedia":["Daunorubicin"],"drugbank":["DB00694"],"chEBI":["41977"]},"childChemblIds":["CHEMBL1563","CHEMBL1200475"],"linkedTargets":{"rows":["ENSG00000131747"],"count":1},"linkedDiseases":{"rows":["MONDO_0000873","MONDO_0044903","EFO_0003812","EFO_0000558","MONDO_0007254","EFO_1001945","EFO_0000209","EFO_0005952","EFO_1001052","MONDO_0003541","EFO_0000565","EFO_0004251","EFO_1001935","EFO_0000339","EFO_0004289","EFO_0000330","MONDO_0020743","EFO_0000094","EFO_0000479","EFO_0000198","EFO_0000221","EFO_0000616","EFO_0003802","EFO_1001779","EFO_0000220","MONDO_0019457","EFO_0000222","EFO_0000223","MONDO_0000870","EFO_1001946","MONDO_0044881","EFO_0000224","EFO_0002429","EFO_0003025","EFO_0003029","EFO_1001934","EFO_0004239","EFO_0003028","MONDO_0044917","EFO_1001936","EFO_0000574","EFO_1001947","EFO_0000218","EFO_0000691","EFO_1002001","MONDO_0004643","EFO_0003811","EFO_0003027"],"count":48},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 3 approved and 40 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL178803","canonicalSmiles":"CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCCCCC3)CC1","inchiKey":"XVGOZDAJGBALKS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BLONANSERIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AD-5423","Blonanserin"],"crossReferences":{"PubChem":["144206818"],"drugbank":["DB09223"]},"linkedTargets":{"rows":["ENSG00000149295","ENSG00000102468","ENSG00000151577"],"count":3},"linkedDiseases":{"rows":["MONDO_0005090"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL187835","canonicalSmiles":"CC(C)[C@@H](NC(N)=O)C(=O)O","inchiKey":"JDXMIYHOSFNZKO-SCSAIBSYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL187835","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01847"],"chEBI":["41469"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL192008","canonicalSmiles":"Cc1ccc(O)cc1C","inchiKey":"YCOXTKKNXUZSKD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"3,4--Xylenol","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["3,4--Xylenol","3,4-Dimethyl-Phenol","3,4-Dimethylphenol"],"crossReferences":{"PubChem":["144208721","144210505","17389286"],"drugbank":["DB04052"],"chEBI":["39839"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL197577","canonicalSmiles":"O=C(O)[C@@H]1C[C@]2(C(=O)O)C=C[C@@H](O)[C@@H](C2)O1","inchiKey":"KRZHNRULRHECRF-JQCUSGDOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL197577","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08648"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL207701","canonicalSmiles":"CCNC(=O)c1n[nH]c(-c2cc(Cl)c(O)cc2O)c1N1CCNCC1","inchiKey":"SORAKBHHTGVZCS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL207701","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06958"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2103821","canonicalSmiles":"O=c1ncc(I)cn1[C@H]1C[C@H](O)[C@@H](CO)O1","inchiKey":"XIJXHOVKJAXCGJ-XLPZGREQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ROPIDOXURIDINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["IPD-R","IPDR","NSC-726188","Ropidoxuridine"],"crossReferences":{"drugbank":["DB06485"]},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2104094","canonicalSmiles":"OC(c1ccc(Cl)cc1)c1cc2ccccc2o1","inchiKey":"KBFBRIPYVVGWRS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CLORIDAROL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Clobenfurol","Cloridarol"],"crossReferences":{"drugbank":["DB13291"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2105825","canonicalSmiles":"CCCN(CCC)C(=O)C(CCC(=O)OCCCN1CCN(CCOC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)CC1)NC(=O)c1ccccc1","inchiKey":"PTXGHCGBYMQQIG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PROGLUMETACIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Proglumetacin","Proglumetacin maleate"],"crossReferences":{"PubChem":["144206876"],"drugbank":["DB13527"],"chEBI":["76263"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2106227","canonicalSmiles":"CCNC1=Nc2ccc(Cl)cc2C(C)(c2ccccc2)O1","inchiKey":"IBYCYJFUEJQSMK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETIFOXINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["36-801","Etifoxine","HOE 36801","HOE-36801"],"crossReferences":{"drugbank":["DB08986"]},"linkedTargets":{"rows":["ENSG00000109158","ENSG00000145863","ENSG00000011677","ENSG00000187730","ENSG00000151834","ENSG00000145864","ENSG00000166206","ENSG00000022355","ENSG00000102287","ENSG00000182256","ENSG00000094755","ENSG00000268089","ENSG00000113327","ENSG00000163285","ENSG00000186297","ENSG00000163288"],"count":16},"linkedDiseases":{"rows":["EFO_0005230"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2106667","canonicalSmiles":"COS(=O)(=O)[O-].COc1cc(N)cn[n+]1-c1ccccc1","inchiKey":"ZEASXVYVFFXULL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMEZINIUM METILSULFATE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL2110922","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Amezinium methyl sulfate","Amezinium metilsulfate","Amezinium metilsulphate"],"crossReferences":{"drugbank":["DB13330"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2106996","canonicalSmiles":"CC(C)N1CCOC(c2cccc(C(F)(F)F)c2)C1","inchiKey":"FVYUQFQCEOZYHZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXAFLOZANE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Oxaflozane"],"crossReferences":{"drugbank":["DB13457"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2107239","canonicalSmiles":"CC(=O)Nc1c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c1I","inchiKey":"OLAOYPRJVHUHCF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IOXITALAMIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AG 58107","AG-58107","Ioxitalamic acid","Ioxithalamic acid"],"crossReferences":{"drugbank":["DB13444"],"chEBI":["83517"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2107309","canonicalSmiles":"Cc1sc[n+](CC(=O)c2ccccc2)c1C.[Cl-]","inchiKey":"MKOMESMZHZNBIZ-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"ALAGEBRIUM CHLORIDE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL2111081","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ALT-711","Alagebrium chloride"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2107337","canonicalSmiles":"Cl.Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21","inchiKey":"UUADYKVKJIMIPA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ENZASTAURIN HYDROCHLORIDE","maximumClinicalTrialPhase":3,"parentId":"CHEMBL300138","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Enzastaurin hcl","Enzastaurin hydrochloride","Enzastaurin monohydrochloride","LY-317615 HYDROCHLORIDE","LY317615 HYDROCHLORIDE"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications."}
{"id":"CHEMBL2107865","drugType":"Cell","blackBoxWarning":false,"name":"AZFICEL-T","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Laviv"],"synonyms":["Autologous cultured fibroblasts","Azficel t","Azficel-t","IT"],"description":"Cell drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL2108237","drugType":"Unknown","blackBoxWarning":false,"name":"CAPSICUM OLEORESIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Capsaicin oleoresin","Capsicum annuum resin","Capsicum capsicum resin","Capsicum longum resin","Capsicum oleoresin","Capsicum oleoresin bpc 1973","Cayenne pepper resin","Chili oleoresin","FEMA NO. 2234","Oleoresin capsicum","Oleoresins of capsicum"],"description":"Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2108282","drugType":"Protein","blackBoxWarning":false,"name":"CATRIDECACOG","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Catridecacog","Novothirteen","Tretten"],"crossReferences":{"DrugCentral":["5134"]},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for hemorrhage and has 2 investigational indications."}
{"id":"CHEMBL2108391","drugType":"Unknown","blackBoxWarning":false,"name":"HONEY","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Feng mi","Fengmi","Honey","Honey absolute","Revamil"],"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."}
{"id":"CHEMBL2108780","drugType":"Small molecule","blackBoxWarning":false,"name":"POLYETHYLENE GLYCOL 4000","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Atpeg 4000","Dulcobalance","Idrolax"],"synonyms":["Carbowax 4000","Forlax","Lipoxol 4000 med","Macrogol 4000","Peg 4000","Peg-85","Peg-90","Pluracare e 4000","Polyethylene glycol 4000","Polyglykol 4000","Sabopeg 4000","Toho peg no. 4000","Unipeg-4000 x"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL2109662","drugType":"Protein","blackBoxWarning":false,"name":"DALANTERCEPT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ACE-041","Dalantercept","Delantercept"],"linkedTargets":{"rows":["ENSG00000263761","ENSG00000163217"],"count":2},"linkedDiseases":{"rows":["EFO_0000681","EFO_0000182","EFO_0004142","EFO_0001378","EFO_0000181"],"count":5},"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL2110922","canonicalSmiles":"COc1cc(N)cn[n+]1-c1ccccc1","inchiKey":"VXROHTDSRBRJLN-UHFFFAOYSA-O","drugType":"Small molecule","blackBoxWarning":false,"name":"AMEZINIUM","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Amezinium cation","Amezinium ion"],"childChemblIds":["CHEMBL2106667"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL215205","canonicalSmiles":"Nc1n[nH]c(N)c1/N=N/c1ccc(O)cc1","inchiKey":"AYZRKFOEZQBUEA-OUKQBFOZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL215205","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07731"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL220396","canonicalSmiles":"COc1cncc(-c2cccc(CNc3cccnc3N)c2)c1","inchiKey":"PGAWZMRRCVSRIM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL220396","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07303"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL224436","canonicalSmiles":"CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1OC(C)=O","inchiKey":"XJSFLOJWULLJQS-NGVXBBESSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"JOSAMYCIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["EN-141","Iosalide","Jomybel","Josamina","Josamycin","Josamycin propionate","Kitasamycin a3","Leucomycin a3","Turimycin a5"],"crossReferences":{"Wikipedia":["Josamycin"],"drugbank":["DB01321"],"chEBI":["31739"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2336325","canonicalSmiles":"CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1","inchiKey":"JUSFANSTBFGBAF-IRXDYDNUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VISTUSERTIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZD-2014","AZD2014","Azd-2014","Vistusertib"],"crossReferences":{"drugbank":["DB11925"]},"linkedTargets":{"rows":["ENSG00000198793"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0003897","Orphanet_145","EFO_0005232","EFO_1001958","EFO_0000503","MONDO_0015686","EFO_0000349","EFO_0000403","MONDO_0007254","EFO_1001512","EFO_0000708","MONDO_0024879","EFO_0000228","MONDO_0008315","EFO_0003060","EFO_0000311","MONDO_0001187","EFO_0005537","EFO_1000251","EFO_0000702","Orphanet_2495","EFO_0000707","MONDO_0002083","EFO_0000519"],"count":25},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 20 investigational indications."}
{"id":"CHEMBL24683","canonicalSmiles":"CCO[C@H](Cc1ccc(OCCN2c3ccccc3Oc3ccccc32)cc1)C(=O)O","inchiKey":"WMUIIGVAWPWQAW-XMMPIXPASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL24683","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06533"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL250270","canonicalSmiles":"COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)C1c1cccc([N+](=O)[O-])c1","inchiKey":"ZDXUKAKRHYTAKV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LERCANIDIPINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Lercanidipine","Lercanil"],"crossReferences":{"PubChem":["50112745","90340703"],"Wikipedia":["Lercanidipine"],"drugbank":["DB00528"]},"childChemblIds":["CHEMBL2106419"],"linkedTargets":{"rows":["ENSG00000157388","ENSG00000081248","ENSG00000102001","ENSG00000151067"],"count":4},"linkedDiseases":{"rows":["MONDO_0001134","EFO_0000319","EFO_0000537"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 2 investigational indications."}
{"id":"CHEMBL250892","canonicalSmiles":"N[C@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O","inchiKey":"SGDBTWWWUNNDEQ-GFCCVEGCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"(R)-MELPHALAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(r)-melphalan","melphalan"],"crossReferences":{"PubChem":["11111435"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL253838","canonicalSmiles":"NC1(c2ccccc2)CCCCC1","inchiKey":"RGZGRPPQZUQUCR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"1-Phenylcyclohexanamine","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["1-Phenylcyclohexanamine"],"crossReferences":{"drugbank":["DB01506"]},"childChemblIds":["CHEMBL545639"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL253976","canonicalSmiles":"C[C@H](Oc1cccc2nc(N)nc(N)c12)c1cccc(Cl)c1","inchiKey":"IDHINEMSCUFEIP-VIFPVBQESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL253976","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07644"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL255590","canonicalSmiles":"NCc1ccc2c(c1)C1(CCN(C(=O)c3ccc(C#Cc4ccccc4)o3)CC1)CO2","inchiKey":"YKTUSHSSKIWDRY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"JNJ-27390467","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["JNJ-27390467"],"crossReferences":{"drugbank":["DB06962"]},"childChemblIds":["CHEMBL402416"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL256147","canonicalSmiles":"CNC(=N)NCCC[C@H](N)C(=O)O","inchiKey":"NTNWOCRCBQPEKQ-YFKPBYRVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TILARGININE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[".omega.-n-methylarginine","L-NMMA","Ng-methylarginine","Ng-monomethyl-l-arginine","Omega-n-methylarginine","Omega-n-methylated arginine","Targinine","Tilarginine"],"crossReferences":{"PubChem":["11111490","11113694","90340995"],"Wikipedia":["Methylarginine"],"drugbank":["DB11815"],"chEBI":["28229"]},"childChemblIds":["CHEMBL3217190","CHEMBL1256175","CHEMBL1744478"],"linkedTargets":{"rows":["ENSG00000164867","ENSG00000089250","ENSG00000007171"],"count":3},"linkedDiseases":{"rows":["EFO_0600064","EFO_1000653","EFO_0009444","Orphanet_232","MONDO_0021187","EFO_0000764","MONDO_0007254","EFO_0004272","EFO_1000859","HP_0031273","EFO_0001073","MONDO_0005148","EFO_0003918"],"count":13},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."}
{"id":"CHEMBL260402","canonicalSmiles":"COC(=O)c1cncn1[C@H](C)c1ccc(I)cc1","inchiKey":"KECBLXVYTIVCTG-SECBINFHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IODOMETOMIDATE I-123, R-","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(r)-4-(123i)iodometomidate","123i-iodometomidate","Iodometomidate i-123, r-"],"crossReferences":{"drugbank":["DB13021"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL26128","canonicalSmiles":"O=P(O)(O)Oc1ccccc1","inchiKey":"CMPQUABWPXYYSH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENYL DIHYDROGEN PHOSPHATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Phosphoric Acid Monophenyl Ester"],"crossReferences":{"PubChem":["144212125"],"drugbank":["DB03298"],"chEBI":["37548"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL263143","canonicalSmiles":"O=C1NC(=O)c2ccc(Br)cc2/C1=C/Nc1ccc(CN2CCCC2)cc1","inchiKey":"JFEKAVPMVOLVTH-UNOMPAQXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL263143","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07156"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL264241","canonicalSmiles":"CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)cc5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)cc2)cc1","inchiKey":"JHVAMHSQVVQIOT-MFAJLEFUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ANIDULAFUNGIN","yearOfFirstApproval":2006,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ecalta","Eraxis"],"synonyms":["Anidulafungin","D-70013","D70013","LY-303366","LY303366","V-echinocandin","VER-002","VER002"],"crossReferences":{"DailyMed":["anidulafungin"],"drugbank":["DB00362"],"chEBI":["55346"]},"childChemblIds":["CHEMBL1275711"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 3 approved and 8 investigational indications."}
{"id":"CHEMBL276443","canonicalSmiles":"CCNC(C)Cc1ccccc1","inchiKey":"YAGBSNMZQKEFCO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETILAMFETAMINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Etilamfetamine","N-ethylamphetamine"],"crossReferences":{"Wikipedia":["Etilamfetamine"],"drugbank":["DB13285"]},"childChemblIds":["CHEMBL1976895"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL309339","canonicalSmiles":"O=C(NO)c1ccccc1O","inchiKey":"HBROZNQEVUILML-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SALICYLHYDROXAMIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2,N-Dihydroxy-Benzamide","Salicylhydroxamic Acid","Salicylic Hydroxamic Acid"],"crossReferences":{"PubChem":["56422153","855524"],"Wikipedia":["Salicylhydroxamic_acid"],"drugbank":["DB03819"],"chEBI":["45615"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL31","canonicalSmiles":"COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12","inchiKey":"XUBOMFCQGDBHNK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GATIFLOXACIN","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"],"classes":["Gastrotoxicity"],"year":2006},"tradeNames":["Gatifloxacin","Tequin","Zymar","Zymaxid"],"synonyms":["AM-1155","BMS-206584-01","BMS-20658401","Gatiflo","Gatifloxacin","Gatifloxacin (sesquihydrate)","Gatifloxacin anhydrous","Gatifloxacin hydrate","Gatifloxacin sesquihydrate","NSC-758701","PD-135432","Zymer"],"crossReferences":{"DailyMed":["gatifloxacin"],"PubChem":["103905240","104171401","124888832","144204535","170465592","26748958","861394"],"Wikipedia":["Gatifloxacin"],"drugbank":["DB01044"],"chEBI":["5280"]},"childChemblIds":["CHEMBL3764608","CHEMBL1974188"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 4 approved and 3 investigational indications. It was withdrawn in United States  in 2006 due to Gastrotoxicity."}
{"id":"CHEMBL316308","canonicalSmiles":"CC(C)(C)C(=O)Nc1cccnc1C(=O)Nc1nccs1","inchiKey":"CAVCWRXFMNCBCM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL316308","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07903"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3183451","canonicalSmiles":"CS(=O)(=O)O.C[C@H]1NCc2cc(-c3ccc4c(=O)c(C(=O)O)cn(C5CC5)c4c3OC(F)F)ccc21.O","inchiKey":"IGTHEWGRXUAFKF-NVJADKKVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GARENOXACIN MESYLATE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL215303","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-284756","BMS-284756-01","Garenoxacin mesilate","Garenoxacin mesilate hydrate","Garenoxacin mesilate monohydrate","Garenoxacin mesylate","Garenoxacin mesylate anhydrous","Garenoxacin methanesulfonate","Geninax","T-3811ME"],"crossReferences":{"PubChem":["144206547","170465937"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3188267","canonicalSmiles":"CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F","inchiKey":"LIOLIMKSCNQPLV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CAPMATINIB","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Capmatinib","INC-280","INC280","INCB-28060","INCB-28060 FREE BASE","Incb-28060","NVP-INC280","NVP-INC280-NX","NYP-INC280-NX"],"crossReferences":{"DailyMed":["capmatinib%20hydrochloride"],"PubChem":["174006562"],"drugbank":["DB11791"]},"childChemblIds":["CHEMBL3989937"],"linkedTargets":{"rows":["ENSG00000105976"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000756","EFO_0000389","EFO_0001421","EFO_0000182","MONDO_0008903","MONDO_0007254","MONDO_0002367","EFO_1001968","EFO_0003060","EFO_0000519"],"count":11},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neoplasm and non-small cell lung carcinoma and has 10 investigational indications."}
{"id":"CHEMBL3337527","canonicalSmiles":"CCCCn1ccc(N2CCC(c3ccccc3)CC2)c(Cl)c1=O","inchiKey":"HYOGJHCDLQSAHX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"JNJ-40411813","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ADX-71149","Jnj-40411813"],"crossReferences":{"drugbank":["DB12059"]},"linkedTargets":{"rows":["ENSG00000164082"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090","MONDO_0002009","HP_0001250","MONDO_0024417"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL3544537","canonicalSmiles":"Oc1ccc(C(c2ccc(O)cc2)c2ccccn2)cc1","inchiKey":"LJROKJGQSPMTKB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIHYDROXYDIPHENYL-PYRIDYL METHANE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dihydroxydiphenyl-pyridyl methane"],"crossReferences":{"drugbank":["DB14232"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545008","drugType":"Small molecule","blackBoxWarning":false,"name":"SAR-260301","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SAR260301","Sar-260301"],"linkedTargets":{"rows":["ENSG00000051382"],"count":1},"linkedDiseases":{"rows":["EFO_0000616"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3545409","drugType":"Small molecule","blackBoxWarning":false,"name":"BVT.115959","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bvt.115959"],"linkedTargets":{"rows":["ENSG00000128271"],"count":1},"linkedDiseases":{"rows":["EFO_0005762"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3601411","canonicalSmiles":"C[C@H]1C[C@@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@@H](C)C[C@@H](C)C4)ccc2C3=NO)C1","inchiKey":"GAPRVZKWPDRAJA-QOPKLXIQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TEGAVIVINT","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BC-2059","Tegavivint"],"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL360328","canonicalSmiles":"C[C@H]1CNCCc2ccc(Cl)cc21","inchiKey":"XTTZERNUQAFMOF-QMMMGPOBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LORCASERIN","yearOfFirstApproval":2012,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Lorcaserin"],"crossReferences":{"DailyMed":["lorcaserin%20hydrochloride"],"PubChem":["144206569","170466882"],"Wikipedia":["Lorcaserin"],"drugbank":["DB04871"],"chEBI":["65353"]},"childChemblIds":["CHEMBL3527027","CHEMBL2095211"],"linkedTargets":{"rows":["ENSG00000147246"],"count":1},"linkedDiseases":{"rows":["EFO_0004319","EFO_0004566","EFO_0003086","EFO_0002610","EFO_0003768","EFO_0000319","EFO_0010702","EFO_0010445","EFO_0001073","EFO_0007191","EFO_0003890","EFO_0003100","EFO_0001421","EFO_0005611"],"count":14},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for obesity and has 11 investigational indications."}
{"id":"CHEMBL3707337","drugType":"Small molecule","blackBoxWarning":false,"name":"FERROUS IODINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ferrous iodine"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3716057","canonicalSmiles":"COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O","inchiKey":"HLWURFKMDLAKOD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GEFAPIXANT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AF-219","Af-219","Gefapixant","R-1646","R1646","RG-1646","RG1646","RO-4926219","RO4926219"],"crossReferences":{"drugbank":["DB15097"]},"childChemblIds":["CHEMBL4594278"],"linkedTargets":{"rows":["ENSG00000109991"],"count":1},"linkedDiseases":{"rows":["HP_0000083","HP_0012735","EFO_0000768","EFO_0008507","EFO_0004616","MONDO_0004979","EFO_0003918"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL37744","canonicalSmiles":"CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1","inchiKey":"OYPPVKRFBIWMSX-SXGWCWSVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ZIMELDINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom, Germany"],"classes":["Hepatotoxicity"],"year":1983},"tradeNames":[],"synonyms":["Cis-zimelidine","Normud","Zelmid","Zimeldine","Zimelidine"],"crossReferences":{"PubChem":["50104953","90340829"],"Wikipedia":["Zimelidine"],"drugbank":["DB04832"]},"childChemblIds":["CHEMBL2355333","CHEMBL1257002","CHEMBL1257115"],"linkedTargets":{"rows":["ENSG00000178394","ENSG00000164270","ENSG00000168830","ENSG00000102468","ENSG00000157219","ENSG00000186090","ENSG00000178084","ENSG00000186038","ENSG00000148680","ENSG00000147246","ENSG00000135312","ENSG00000135914","ENSG00000179546","ENSG00000149305","ENSG00000158748","ENSG00000179097","ENSG00000166736"],"count":17},"linkedDiseases":{"rows":["EFO_0003761"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for unipolar depression. It was withdrawn in United Kingdom, Germany  in 1983 due to Hepatotoxicity."}
{"id":"CHEMBL378927","canonicalSmiles":"Cc1ccc(NS(=O)(=O)c2ccccc2)c(C(=O)O)c1","inchiKey":"HXQLTRSIZRSFTR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL378927","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07313"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3889654","canonicalSmiles":"O=C(Nc1cnn2ccc(N3CCC[C@@H]3c3cc(F)ccc3F)nc12)N1CC[C@H](O)C1","inchiKey":"NYNZQNWKBKUAII-KBXCAEBGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LAROTRECTINIB","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["ARRY-470","BAY-2757556","BAY2757556","LOXO-101","Larotrectinib","Loxo-101"],"crossReferences":{"DailyMed":["larotrectinib%20sulfate"],"drugbank":["DB14723"]},"childChemblIds":["CHEMBL3989939"],"linkedTargets":{"rows":["ENSG00000140538","ENSG00000148053","ENSG00000198400"],"count":3},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0100342","EFO_0000311","EFO_0009708"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 1 investigational indication."}
{"id":"CHEMBL389051","canonicalSmiles":"C#CCN(Cc1ccc2[nH]c(N)nc(=O)c2c1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1","inchiKey":"LTKHPMDRMUCUEB-IBGZPJMESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CB-3717","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CB-3717","TCMDC-131823"],"crossReferences":{"drugbank":["DB03541"],"chEBI":["3258"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3950712","canonicalSmiles":"COc1cc(N)c(Cl)cc1C(=O)NCC1CCN(CCCn2ccnn2)CC1","inchiKey":"AULLTYAISZREAX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DA-6886","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Da-6886"],"crossReferences":{"drugbank":["DB12853"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL39677","canonicalSmiles":"c1ccc2nc3ccccc3cc2c1","inchiKey":"DZBUGLKDJFMEHC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ACRIDINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Acridine","NSC-3408"],"crossReferences":{"PubChem":["124892352","26755289"],"Wikipedia":["Acridine"],"chEBI":["36420"]},"childChemblIds":["CHEMBL4103461"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3971095","canonicalSmiles":"COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2cc(F)c3c(c2)O[C@@H](c2cnc(C4CC4)s2)n2c-3cc3cc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)ccc32)[nH]1)C(C)C","inchiKey":"AXWDHVUJXNOWCC-RAEGKSCOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3971095","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB11713"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3989751","drugType":"Small molecule","blackBoxWarning":false,"name":"NEOMYCIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Fradiomycin","Kaomycine","Neolate","Neomas","Neomin","Neomycin","Pimavecort","Vonamycin"],"childChemblIds":["CHEMBL3989602","CHEMBL3989533"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 3 approved and 6 investigational indications."}
{"id":"CHEMBL3990854","drugType":"Small molecule","blackBoxWarning":false,"name":"CERIUM OXALATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"childChemblIds":["CHEMBL3833363"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4094894","canonicalSmiles":"CC(C)c1cccc([C@H](C)C2CC2)c1O","inchiKey":"BMEARIQHWSVDBS-SNVBAGLBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HSK-3486","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["HSK-3486","HSK-3486, (R)-","HSK3486","Hsk-3486","Hsk3486"],"linkedTargets":{"rows":["ENSG00000109158","ENSG00000145863","ENSG00000011677","ENSG00000187730","ENSG00000151834","ENSG00000145864","ENSG00000166206","ENSG00000022355","ENSG00000102287","ENSG00000182256","ENSG00000094755","ENSG00000268089","ENSG00000163285","ENSG00000113327","ENSG00000186297","ENSG00000163288"],"count":16},"linkedDiseases":{"rows":["EFO_0003086"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL41631","canonicalSmiles":"NCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12","inchiKey":"IDEHCMNLNCJQST-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL41631","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["11110730","11113468","124879160","124879162","26751692","50104383"],"drugbank":["DB04513"]},"childChemblIds":["CHEMBL513116"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL426643","canonicalSmiles":"Cc1cc[nH]c1","inchiKey":"FEKWWZCCJDUWLY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL426643","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01932"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4297269","canonicalSmiles":"CN1C(=O)[C@@H](NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)N=C(c2ccccc2)c2ccccc21","inchiKey":"AYOUDDAETNMCBW-GSHUGGBRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BMS-906024","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AL-101","AL101","Al-101","Al101","BM-0018","BM0018","BMS 906024","BMS-906024","Bms 906024","Bms-906024","Osugacestat"],"crossReferences":{"drugbank":["DB12006"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4297304","canonicalSmiles":"COc1ccc2nc3c(nc2c1)O[C@@H]1C[C@H]2C(=O)N[C@]4(C(=O)NS(=O)(=O)C5(C)CC5)C[C@H]4/C=C/CCCCC[C@H](NC(=O)O[C@@H]4CCC[C@H]4CCCCC3)C(=O)N2C1","inchiKey":"BLFKRFGLQFYXDF-WAZRELCSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MK-6325","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MK 6325","Mk-6325"],"crossReferences":{"drugbank":["DB15249"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297419","canonicalSmiles":"CCCCCCCC(C(=O)c1ccccc1)N1CCCC1","inchiKey":"RYJXAZXFWIWTOJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":".ALPHA.-PYRROLIDINONONANOPHENONE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[".alpha.-pnp",".alpha.-pyrrolidinononanophenone","Pv-10"],"crossReferences":{"drugbank":["DB05531"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297490","canonicalSmiles":"[2H]C([2H])([2H])NC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1","inchiKey":"MLDQJTXFUGDVEO-FIBGUPNXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CM-4307","maximumClinicalTrialPhase":3,"parentId":"CHEMBL1336","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CM-4307","Cm-4307","Donafenib"],"crossReferences":{"drugbank":["DB15414"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL4297827","drugType":"Unknown","blackBoxWarning":false,"name":"SGN-CD352A","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Pbd dimer adc sgn-cd352a","Pbd-based anti-cd352","Sgn cd352a","Sgn-cd352a"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297837","drugType":"Antibody","blackBoxWarning":false,"name":"TALACOTUZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CSL-362","CSL362","Csl362","JNJ-56022473","Jnj-56022473","Talacotuzumab"],"linkedTargets":{"rows":["ENSG00000185291"],"count":1},"linkedDiseases":{"rows":["EFO_0000198","EFO_0002690","EFO_0000222"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4297970","drugType":"Antibody","blackBoxWarning":false,"name":"MELRILIMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CNTO-7160","GSK-3772847","GSK3772847","Gsk-3772847","Gsk3772847","Melrilimab"],"description":"Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4298058","drugType":"Protein","blackBoxWarning":false,"name":"BEMPEGALDESLEUKIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aldesleukin prodrug nktr-214","Bempegaldesleukin","NKTR-214","NKTR-214 PRODRUG","Nktr 214","Nktr-214"],"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications."}
{"id":"CHEMBL4298095","drugType":"Antibody","blackBoxWarning":false,"name":"NIMACIMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["JNJ-2463","JNJ2463","Nimacimab","RYI-018","RYI018","Ryi-018"],"linkedTargets":{"rows":["ENSG00000118432"],"count":1},"linkedDiseases":{"rows":["EFO_1000948"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL429852","canonicalSmiles":"CC(C)C[C@@H](NC(=N)N)C(=O)NCC(=O)N1CCC(c2cc(-c3ccc(OCc4ccc(C(=O)O)o4)c(Cl)c3Cl)nn2C)CC1","inchiKey":"VNZHOIDQBPFEJU-OAQYLSRUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SP-4206","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SP-4206"],"crossReferences":{"drugbank":["DB02581"],"chEBI":["47417"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL432600","canonicalSmiles":"C=C1/C(=C\\C=C2/CCC[C@]3(C)[C@@H]([C@@H](C)OCCCC(O)(CC)CC)CC[C@@H]23)C[C@@H](O)C[C@@H]1O","inchiKey":"KLZOTDOJMRMLDX-YBBVPDDNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LEXACALCITOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Lexacalcitol"],"crossReferences":{"drugbank":["DB03451"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL437526","canonicalSmiles":"CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN2C(=O)CC[C@H](NC(=O)c3nccc4ccccc34)C(=O)N12","inchiKey":"CXAGHAZMQSCAKJ-WAHHBDPQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PRALNACASAN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["HMR-3480","HMR3480","HMR3480/VX-740","Pralnacasan","VX-740"],"crossReferences":{"drugbank":["DB04875"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL454446","canonicalSmiles":"CO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(/C=C\\c3scnc3C)CS[C@H]12)c1csc(N)n1","inchiKey":"AFZFFLVORLEPPO-UVYJNCLZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEFDITOREN PIVOXIL","yearOfFirstApproval":2001,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Meiact","Spectracef"],"synonyms":["CDTR-PI","Cefditoren","Cefditoren pivaloyloxymethyl ester","Cefditoren pivoxil","ME-1207","ME1207","NSC-759098"],"crossReferences":{"DailyMed":["cefditoren%20pivoxil"],"PubChem":["144206748"],"chEBI":["560555"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 4 approved and 1 investigational indication."}
{"id":"CHEMBL4559134","canonicalSmiles":"COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1","inchiKey":"XIIOFHFUYBLOLW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SELPERCATINIB","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Retevmo"],"synonyms":["LOXO-292","LY-3527723","LY3527723","Loxo-292","Ret inhibitor loxo-292","Selpercatinib"],"crossReferences":{"DailyMed":["selpercatinib"]},"linkedTargets":{"rows":["ENSG00000165731","ENSG00000170759","ENSG00000108091"],"count":3},"linkedDiseases":{"rows":["MONDO_0002108","MONDO_0015277","EFO_0003060","EFO_0000311"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved indications."}
{"id":"CHEMBL4594306","drugType":"Antibody","blackBoxWarning":false,"name":"DILPACIMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ABT-165","Abt 165","Abt-165","Dilpacimab","PR-1283233"],"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4594538","drugType":"Unknown","blackBoxWarning":false,"name":"DV-281","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["DV-281","DV281","Dv-281","Dv281"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4594551","drugType":"Unknown","blackBoxWarning":false,"name":"HUMAN RECOMBINANT BONE MORPHOGENETIC PROTEIN 4","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Hrbmp4","Human recombinant bone morphogenetic protein 4","R-hbmp4"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4594553","drugType":"Unknown","blackBoxWarning":false,"name":"IBI-188","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["IBI-188","IBI188","Ibi-188","Ibi188","LETAPLIMAB"],"description":"Unknown drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4650242","drugType":"Gene","blackBoxWarning":false,"name":"EZALADCIGENE RESOPARVOVEC","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ezaladcigene resoparvovec","NBIb-1817","VY-AADC02"],"description":"Gene drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4650364","drugType":"Small molecule","blackBoxWarning":false,"name":"YTTRIUM Y-90","maximumClinicalTrialPhase":1,"parentId":"CHEMBL4650626","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Yttrium (90 y)","Yttrium y-90","Yttrium-90"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4650455","drugType":"Unknown","blackBoxWarning":false,"name":"GANULAMERAN","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BNT-162B3","BNT162B3","Bnt162b3","Ganulameran"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL46516","canonicalSmiles":"O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2","inchiKey":"QOYHHIBFXOOADH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLUSPIRILENE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Imap","Redeptin"],"synonyms":["Fluspirilene","Imap","MCN-JR-6218","R 6218","R-6218","Redeptin"],"crossReferences":{"PubChem":["104171151","11111163","11112501","11532937","124880064","124880066","144203693","170466307","174006661","26753577","26753578","50106303","50106304","56422781","85231040","90341058"],"Wikipedia":["Fluspirilene"],"drugbank":["DB04842"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for psychosis and has 4 investigational indications."}
{"id":"CHEMBL4802141","canonicalSmiles":"C=C(CC(NC(=O)c1ccc(CCc2ccc3nc(N)nc(N)c3c2)cc1)C(=O)O)C(=O)O","inchiKey":"NAWXUBYGYWOOIX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CH-1504","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AA-243","CH 1504","Ch-1504","M-trex","Mobiletrex","Tridam"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL482035","canonicalSmiles":"COC(=O)c1cc(OC)c2c(c1-c1c(CO)cc(OC)c3c1OCO3)OCO2","inchiKey":"KXMTXZACPVCDMH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BICYCLOL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bicyclol"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL489156","canonicalSmiles":"COc1cc(OC)c(/C=C2/C(=O)Nc3ccccc32)c(OC)c1","inchiKey":"JBJYTZXCZDNOJW-JLHYYAGUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL489156","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["11111311","50106919","50106920","85231087","90340751"],"drugbank":["DB03083"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL497834","canonicalSmiles":"CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@H](O)CC1=C[C@@H]3O","inchiKey":"OYXZMSRRJOYLLO-KGZHIOMZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"7Beta-Hydroxycholesterol","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["7Beta-Hydroxycholesterol"],"crossReferences":{"drugbank":["DB04706"],"chEBI":["42989"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL525194","canonicalSmiles":"c1cnn2ncc(-c3ccnc(NC4CC4)n3)c2c1","inchiKey":"CAGHIASAHLPQMS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL525194","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07164"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL531472","canonicalSmiles":"CC[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12","inchiKey":"LJOQGZACKSYWCH-LHHVKLHASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL531472","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB15300"]},"childChemblIds":["CHEMBL533007"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL582878","canonicalSmiles":"O=C(O)CCCc1c[nH]c2ccccc12","inchiKey":"JTEDVYBZBROSJT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"INDOLE-3-BUTYRIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Indole-3-Butyric Acid"],"crossReferences":{"PubChem":["144211604","174006785","26757715"],"Wikipedia":["Indole-3-butyric_acid"],"drugbank":["DB02740"],"chEBI":["33070"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL622","canonicalSmiles":"CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3","inchiKey":"NNYBQONXHNTVIJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"ETODOLAC","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ebretin","Etodolac","Etolyn","Etopan xl","Lodine","Lodine sr","Lodine xl","Ramodar"],"synonyms":["(rs)-etodolic acid","AY-24,236","AY-24-236","AY-24236","Eccoxolac","Edolan","Etodolac","Etodolic acid","Flancox","Lodin xl","NIH-9918","NSC-282126","Napilac","Tedolan","Ultradol","Zedolac"],"crossReferences":{"DailyMed":["etodolac"],"PubChem":["144209416","170464915","174007213","50105240","56422166","85231029","855612","90340662"],"Wikipedia":["Etodolac"],"drugbank":["DB00749"],"chEBI":["4909"]},"linkedTargets":{"rows":["ENSG00000073756"],"count":1},"linkedDiseases":{"rows":["EFO_0002970","EFO_0000685","Orphanet_79292","EFO_0003860","EFO_0009582","EFO_0000182","EFO_0004142","HP_0003419","EFO_0003843","EFO_0005755","MONDO_0005178","EFO_0002609"],"count":12},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 5 approved and 7 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL643","canonicalSmiles":"CC(CN1c2ccccc2Sc2ccccc21)N(C)C","inchiKey":"PWWVAXIEGOYWEE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"PROMETHAZINE","yearOfFirstApproval":1951,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Dimapp","Diphergan","Fargan","NSC-30321","Phenergan","Proazamine","Procit","Prometazin","Promethacon","Promethazine","Promethegan","Protazine","Prothazin","RP-3277","Remsed","Vallergine","Zipan-25","Zipan-50"],"crossReferences":{"DailyMed":["promethazine%20hydrochloride"],"PubChem":["104171211","124881100","124881103","144203778","170465107","26752304","50105224","90341785"],"TG-GATEs":["110"],"Wikipedia":["Promethazine"],"drugbank":["DB01069"],"chEBI":["8461"]},"childChemblIds":["CHEMBL1200750"],"linkedTargets":{"rows":["ENSG00000196639"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0006928","HP_0000989","HP_0000726","MONDO_0005271","EFO_1000948","EFO_0000274","MONDO_0004900","EFO_0003843","EFO_0004698","EFO_1000971","EFO_0000384","HP_0002018","MONDO_0100431","EFO_0005531","MONDO_0002050","HP_0002017","EFO_0004888","HP_0003419","EFO_0007141","HP_0002013","EFO_1001188","EFO_0005230","EFO_0003956","MONDO_0005475"],"count":25},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and has 9 approved and 15 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL679","canonicalSmiles":"CNC[C@H](O)c1ccc(O)c(O)c1","inchiKey":"UCTWMZQNUQWSLP-VIFPVBQESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EPINEPHRINE","yearOfFirstApproval":1976,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Adren co","Adrenaclick","Adrenalin","Ana-Kit","Ana-guard","Anapen","Anaphylactic shock drug kit","Asma-vydrin","Asthmahaler","Auvi-q","Bronkaid mist","Brovon","Emerade","Epi e z pen jr","Epinephrine","Epinephrine (copackaged)","Epipen","Epipen e z pen","Epipen jr","Epipen jr.","Eppy","Gppe inh soln","Jext","Medihaler-epi","Primatene","Primatene mist","Riddobron","Riddofan","Rybarvin","Simplene","Soln made to rybarvin for","Sus-Phrine","Sus-Phrine Sulfite-Free","Sus-phrine sulfite free","Symjepi","Twinject 0.15","Twinject 0.3"],"synonyms":["(-)-(r)-epinephrine","(-)-epinephrine","Adrenaline","Adrenalinum","Epinephrine","Epinephrine hcl","Epinephrine hydrochloride","Epinephrinum","Glauposine","L-epinephrine hydrochloride","Levo-methylaminoethanolcatechol","NSC-62786","Nephridine","Racepinefrine, (r)-","Sus-phrine sulphite-free","Susphrine","Tonogen","Twinject"],"crossReferences":{"DailyMed":["epinephrine","epinephrine%20bitartrate"],"PubChem":["11111154","144205115","170464973","26754418","26754419","26754420","29215202","90341589"],"Wikipedia":["Epinephrine"],"drugbank":["DB00668"],"chEBI":["28918"]},"childChemblIds":["CHEMBL3183376","CHEMBL1256958","CHEMBL1200818","CHEMBL227634"],"linkedTargets":{"rows":["ENSG00000184160","ENSG00000274286","ENSG00000169252","ENSG00000171873","ENSG00000170214","ENSG00000120907","ENSG00000043591","ENSG00000188778","ENSG00000150594"],"count":9},"linkedDiseases":{"rows":["HP_0002105","EFO_1001139","EFO_0009540","HP_0002239","EFO_0007486","EFO_1001178","EFO_0011061","EFO_0004278","MONDO_0003061","EFO_0009840","HP_0011950","HP_0100543","EFO_0000544","EFO_0005306","EFO_1000786","MONDO_0100053","EFO_0004616","EFO_1000652","EFO_0009552","EFO_0000400","HP_0011499","EFO_1001250","EFO_0005854","HP_0012532","HP_0002619","HP_0001742","EFO_0000546","MP_0001914","HP_0006536","EFO_1000391","MONDO_0004979","EFO_0004209","EFO_0000516","EFO_0003033","HP_0031273","EFO_0009676","EFO_0005672","EFO_0005251","EFO_1001222","EFO_0004610","EFO_0006834","MONDO_0007254","MONDO_0005271","EFO_0009846","EFO_0008553","EFO_0002950","MONDO_0001056","EFO_0005531","MONDO_0022394","MONDO_0002050","HP_0001385","EFO_0003144","MONDO_0005129","EFO_1001417","EFO_0000616","EFO_0004269","EFO_0004198","EFO_0000319","EFO_0005532","EFO_0003843","EFO_0003060","EFO_0007149","EFO_0007227","EFO_0004287","EFO_0000649","EFO_1001087","MONDO_0021400","MONDO_0005178","EFO_0009492","EFO_0003956"],"count":70},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 19 approved and 28 investigational indications."}
{"id":"CHEMBL75880","canonicalSmiles":"C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1","inchiKey":"CYXKNKQEMFBLER-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PERHEXILINE","yearOfFirstApproval":1974,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["Spain"," United Kingdom"],"classes":["Hepatotoxicity"," Neurotoxicity"],"year":1985},"tradeNames":[],"synonyms":["Perhexiline"],"crossReferences":{"PubChem":["174006795"],"TG-GATEs":["45"],"Wikipedia":["Perhexiline"],"drugbank":["DB01074"],"chEBI":["35553"]},"childChemblIds":["CHEMBL1334033"],"linkedTargets":{"rows":["ENSG00000205560","ENSG00000198793","ENSG00000157184"],"count":3},"linkedDiseases":{"rows":["EFO_0003144","EFO_0000319","EFO_0000538","EFO_1001458","EFO_1000899"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and is indicated for cardiovascular disease and has 4 investigational indications. It was withdrawn in Spain and  United Kingdom initially in 1985 due to Hepatotoxicity and  Neurotoxicity."}
{"id":"CHEMBL847","canonicalSmiles":"CC(C)NCC1CCc2cc(CO)c([N+](=O)[O-])cc2N1","inchiKey":"XCGYUJZMCCFSRP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXAMNIQUINE","yearOfFirstApproval":1980,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Vansil"],"synonyms":["NSC-352888","Oxamniquine","Oxamniquinum","UK-4261","UK-4271"],"crossReferences":{"PubChem":["144204144","26665195"],"Wikipedia":["Oxamniquine"],"drugbank":["DB01096"],"chEBI":["78416"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for helminthiasis."}
{"id":"CHEMBL88","canonicalSmiles":"O=P1(N(CCCl)CCCl)NCCCO1","inchiKey":"CMSMOCZEIVJLDB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CYCLOPHOSPHAMIDE","yearOfFirstApproval":1959,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cytoxan"],"synonyms":["Cyclophosphamide","Cytoxan","Neosar"],"crossReferences":{"DailyMed":["cyclophosphamide"],"PubChem":["174007432","50105634","85230959","87150","90341534"],"TG-GATEs":["24"],"Wikipedia":["Cyclophosphamide"],"drugbank":["DB00531"],"chEBI":["4027"]},"childChemblIds":["CHEMBL1200796","CHEMBL2364721"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 10 approved and 224 investigational indications."}
{"id":"CHEMBL92963","canonicalSmiles":"C=C(Br)CC1(C(C)C)C(=O)NC(=O)N(C)C1=O","inchiKey":"WGMASVSHOSNKMF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NARCOBARBITAL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Enibomal","Narcobarbital","Narcovene","Pronarcon"],"crossReferences":{"Wikipedia":["Narcobarbital"],"drugbank":["DB13229"],"chEBI":["81294"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL976","canonicalSmiles":"O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1","inchiKey":"FSVJFNAIGNNGKK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PRAZIQUANTEL","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Biltricide","Cesol","Cestocur","Cisticid","Cysticide","Droncit"],"synonyms":["EMBAY 8440","EMBAY-8440","NSC-757285","Praziquantel","Praziquantelum"],"crossReferences":{"DailyMed":["praziquantel"],"PubChem":["144204211","144209148","144213244","170464906","174006188","26747203","50105220","85231186","855582","858012","90341571"],"Wikipedia":["Praziquantel"],"drugbank":["DB01058"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 4 approved and 3 investigational indications."}
